Clinical Guidelines and Standards Guidelines by Clinical Area

The 2022 hormone therapy position statement of The North American Menopause Society

“The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel

Published July 2022 Menopause (New York, N.Y.), 29(7), 767-794
DOI 10.1097/GME.0000000000002028 PMID 35797481

RRM Academy Synopsis

NAMS finds hormone therapy favorable for hot flashes, bone loss under 60

A 2022 menopause society panel finds that hormone therapy offers more benefit than risk among women under 60 with no contraindications. The same holds for women within 10 years of menopause onset. The benefit applies to bothersome hot flashes and night sweats, and to preventing bone loss.

Key Findings

  • For women starting hormone therapy after 60 or over 10 years past menopause onset, the ratio appears less favorable because of greater absolute risks of coronary heart disease, stroke, clots, and dementia.
  • Risk shifts with the hormone type, the amount taken, length of use, delivery route, start time, and whether a progestogen is added.
  • The panel names hormone therapy the most effective option for vasomotor symptoms (VMS) and for the genitourinary syndrome of menopause, and reports a role in bone and fracture protection.
  • For genitourinary symptoms that over-the-counter products leave unrelieved in women without indications for systemic therapy, the panel recommends low-dose vaginal estrogen or alternatives such as vaginal dehydroepiandrosterone.

Interpretation

The synopsis draws on the published abstract. The statement is a consensus from clinicians and researchers recruited by the North American Menopause Society (NAMS). They updated the 2017 statement, weighed new studies, and graded the strength of evidence. The NAMS Board of Trustees approved the result. The panel calls for individualized treatment with periodic reevaluation. The panel recommends that longer use rest on a documented reason, for example persistent VMS, decided together with the patient.

RRM Context

The panel lists whether a progestogen is used among the factors that change risk. Progesterone is the body's own hormone. Progestins are synthetic alterations of it. Research that groups them together blurs a real difference. Restorative reproductive medicine also fits care to the individual woman and her timing.

Abstract

"The 2022 Hormone Therapy Position Statement of The North American Menopause Society" (NAMS) updates "The 2017 Hormone Therapy Position Statement of The North American Menopause Society" and identifies future research needs. An Advisory Panel of clinicians and researchers expert in the field of women's health and menopause was recruited by NAMS to review the 2017 Position Statement, evaluate new literature, assess the evidence, and reach consensus on recommendations, using the level of evidence to identify the strength of recommendations and the quality of the evidence. The Advisory Panel's recommendations were reviewed and approved by the NAMS Board of Trustees.Hormone therapy remains the most effective treatment for vasomotor symptoms (VMS) and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture. The risks of hormone therapy differ depending on type, dose, duration of use, route of administration, timing of initiation, and whether a progestogen is used. Treatment should be individualized using the best available evidence to maximize benefits and minimize risks, with periodic reevaluation of the benefits and risks of continuing therapy.For women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome VMS and prevention of bone loss. For women who initiate hormone therapy more than 10 years from menopause onset or who are aged older than 60 years, the benefit-risk ratio appears less favorable because of the greater absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia. Longer durations of therapy should be for documented indications such as persistent VMS, with shared decision-making and periodic reevaluation. For bothersome genitourinary syndrome of menopause symptoms not relieved with over-the-counter therapies in women without indications for use of systemic hormone therapy, low-dose vaginal estrogen therapy or other therapies (eg, vaginal dehydroepiandrosterone or oral ospemifene) are recommended.

Topics

Related research

Clinical Guidelines and Standards › Guidelines by Clinical Area › Bone and Endocrine Guidelines · Perimenopause and Menopause › Hormone Therapy › Benefits and Risks · Therapeutics › Hormonal Agents › Estrogen Preparations
PMID 35797481 35797481 DOI 10.1097/GME.0000000000002028 10.1097/GME.0000000000002028 “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel et al. 2022, “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel 2022